

Disclaimer: This document is an English translation of the original document in Japanese and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original in Japanese, the original shall prevail in all respects.



April 21, 2023

To whom it may concern:

Company name KISSEI PHARMACEUTICAL CO., LTD.  
 Representative Mutsuo Kanzawa, Chairman and CEO  
 (Stock code 4547; Prime Market, Tokyo Stock Exchange)  
 Contact Takahide Kitahara, Managing Director,  
 Department Manager of Corporate Finance and Management Department  
 (Telephone +81-263-25-9081)

### Notice Concerning Revisions to Financial Results Forecast

In light of the recent trends in financial results and other factors, KISSEI PHARMACEUTICAL CO., LTD. (the “Company”) announces that it has revised the financial results forecast announced on November 8, 2022 as follows.

● Revisions to the Financial Results Forecast

Revisions to the Consolidated Financial Results Forecast Figures for the Fiscal Year Ended March 31, 2023  
 (April 1, 2022 – March 31, 2023)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Basic earnings per share
Previously announced forecast (A)	Million yen 68,500	Million yen 500	Million yen 2,100	Million yen 10,800	Yen 234.19
Revised forecast (B)	67,400	(1,200)	500	10,500	227.69
Change (B-A)	(1,100)	(1,700)	(1,600)	(300)	
Change rate (%)	(1.6%)	—	(76.2%)	(2.8%)	
(Reference) Results for the previous fiscal year (Fiscal year ended March 31, 2022)	65,381	(1,402)	562	12,921	280.20

Reasons for the Revision

Net sales for the fiscal year ended March 31, 2023 are expected to be lower than the initial forecast due to technical fees deferred to the following fiscal year, together with the overall sales of pharmaceuticals expected to be lower than the forecast, despite the growth of new product sales in the Pharmaceutical Business. Regarding profit, the Company expects an operating loss and a decrease in ordinary income compared to the initial forecast due to the failure to achieve net sales and the anticipated increase in the cost of sales ratio from 50.2% which was initially expected, to the 52% range. Profit attributable to owners of parent for the fiscal year ended March 31, 2023 is expected to decrease by 2.8% due to an increase in gain on sales of investment securities.

(Note) The above forecasts are based on information available to the Company as of the date of publication of this document and certain assumptions as of the date of publication of this document on uncertainties that may have an impact on future financial results. Actual results may differ greatly from these forecasts due to a variety of factors in the future.